Array to Present Updated Phase 3 Melanoma Trial Data at ASCO

Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting

– Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months –

– Landmark analysis estimates 47% and 39% of patients alive at 3 and 4 years, respectively –

– Oral poster presentation June 3, 2019 –

https://www.morningstar.com/news/pr-news-wire/PRNews_20190529LA66597/array-biopharma-announces-presentation-of-updated-overall-survival-from-the-phase-3-columbus-trial-of-braftovi-mektovi-in-advanced-brafmutant-melanoma-at-2019-asco-annual-meeting.html